Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trustpilot lifts FY margin guidance, shares spark

(Sharecast News) - Trustpilot surged on Tuesday as the review website upgraded its full-year margin guidance, reporting a jump in first-half bookings and revenue. In an update for the six months to 30 June, the company said it expects to report a 19% year-on-year jump in bookings to $140m, with UK bookings up 15%, Europe and Rest of World up 19% and North American bookings ahead 18%.

Trustpilot also said it expects first-half revenue growth of 21% to $123m.

The group said it was lifting its full-year 2025 adjusted EBITDA margin guidance to 14%. This compares with consensus expectations of 13.4%.

Chief executive Adrian Blair said: "The broad nature of our SaaS business model continues to prove its resilience, enabling us to deliver good growth and retention, particularly in the enterprise segment, combined with strong cash generation and operating leverage.

"We are pleased with our first half performance and as we continue to annualise the package migration which benefited last year's bookings, we now expect full year adjusted EBITDA margin to be 14%. We remain confident in the significant growth opportunities ahead in our focus markets and beyond."

At 0955 BST, the shares were up 13.5% at 286.64p.

Following the update, Berenberg - which rates the stock at 'buy' - lifted its FY25, FY26 and FY27 revenue forecasts by 2%, 1% and 1% respectively, and its adjusted EBITDA forecasts by 5%, 7% and 6% respectively.

"For a competitively advantaged software business that is expected to grow its revenues at a mid-teens year-on-year rate, 5.3x FY25 EV/sales is, in our view, an undemanding valuation," the bank said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.